ClinicalTrials.Veeva

Find clinical trials for Adenocarcinoma in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Charlotte, NC, USA:

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: gemcitabine
Drug: nab-paclitaxel

Phase 2

Astellas
Astellas

Charlotte, North Carolina, United States and 137 other locations

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trast...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Neoplasms
Drug: Oxaliplatin
Drug: Cisplatin

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 191 other locations

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It...

Enrolling
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Drug: tucatinib
Drug: trastuzumab

Phase 1, Phase 2

Seagen
Seagen

Charlotte, North Carolina, United States and 21 other locations

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, gastroesophageal adenocarcinoma...

Enrolling
Gastroesophageal Adenocarcinoma
Advanced Solid Tumors
Drug: ABBV-400
Drug: Trifluridine/Tipiracil

Phase 1

AbbVie
AbbVie

Huntersville, North Carolina, United States and 79 other locations

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.

Enrolling
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Huntersville, North Carolina, United States and 6 other locations

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

adenocarcinoma. Enrollment in the expansion cohorts is limited to the following tumor types: endometrial, SCCHN, CRC, and a basket cohort i...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: TPST-1495 once daily or on intermittent schedule
Drug: Pembrolizumab

Phase 1

Tempest Therapeutics

Huntersville, North Carolina, United States and 10 other locations

Study of INCB123667 in Subjects With Advanced Solid Tumors

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy...

Enrolling
Solid Tumors
Drug: INCB0123667

Phase 1

Incyte
Incyte

Huntersville, North Carolina, United States and 33 other locations

Locations recently updated

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Drug: Bemarituzumab
Drug: Placebo

Phase 3

Amgen
Amgen

Charlotte, North Carolina, United States and 300 other locations

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 in subjects with ad...

Enrolling
Esophageal Adenocarcinoma
Metastatic Cancer
Drug: TJ033721

Phase 1

I-Mab Biopharma

Huntersville, North Carolina, United States and 18 other locations

Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, p...

Enrolling
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Drug: PT199
Drug: Tislelizumab

Phase 1

Phanes Therapeutics

Huntersville, North Carolina, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems